Thursday, 24 September 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 5, 2026

Chronic Rhinosinusitis with Nasal Polyps Market Shows Strong Upward Momentum During the Forecast Period (2026-2036) as Demand for Advanced Therapies Rises | DelveInsight

View original at finance.yahoo.com
Chronic Rhinosinusitis with Nasal Polyps Market Shows Strong Upward Momentum During the Forecast Period (2026-2036) as Demand for Advanced Therapies Rises | DelveInsight The chronic rhinosinusitis with nasal polyps market growth is being driven by rising disease prevalence, greater awareness, and improved diagnostic ra…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • GSK has expressed continued confidence in depemokimab's potential for CRSwNP and is maintaining discussions with the FDA

    80% confidence

  • The dynamics of the CRSwNP market are expected to change in the coming years due to the launch of emerging therapies such as Depemokimab, Verekitug (UPB-101), Lunsekimig, LY3650150, and others

    80% confidence

  • The US had around 2 million diagnosed prevalent cases of CRSwNP in 2025

    80% confidence

  • CRSwNP is expected to see a rising disease burden over the forecast period (2026-2036), driven primarily by increasing prevalence, improved diagnosis, and evolving treatment approaches

    80% confidence

  • The United States accounted for the largest CRSwNP treatment market size in 2025, compared to other major markets

    80% confidence

  • The 7MM accounted for 4.5 million diagnosed prevalent cases of CRSwNP in 2025, which are expected to increase during the study period

    80% confidence

  • Treatment strategies are shifting beyond conventional intranasal corticosteroids, systemic steroids, and surgery toward targeted biologic therapies, enabling more personalized and sustained disease control for patients

    80% confidence

  • Gender distribution of CRSwNP in the US shows male predominance with 55% of diagnosed prevalent cases being males

    80% confidence

  • The total chronic rhinosinusitis with nasal polyps treatment market size is expected to grow positively by 2036 in the leading markets

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Go Mainstream, But Trustworthy Data Access Lags Adoption
A wave of enterprise AI agent activity — fresh funding (Latitude's $35M Series A), a run of CB Insights CEO interviews spotlighting fintech- and healthcare-focused agent startups (Covecta, Penguin AI, Maisa AI), and major platform partnerships (Microsoft-Mistral, Manulife-Microsoft AI governance, Siemens-NVIDIA agentic EDA, Box's agent security controls) — signals agentic AI moving from pilot to production across financial and enterprise workflows. Yet Google Cloud's own research shows adoption is outrunning data readiness (companies average AI access to only 45% of their data, with 'data laggards' capped near 30%), while insider selling at incumbent C3.ai hints at mixed investor conviction even as the broader ecosystem accelerates.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,305 source documents archived
Query this data → isubstrate.com
Chronic Rhinosinusitis with Nasal Polyps Market Shows Strong Upward Momentum During the Forecast Period (2026-2036) as Demand for Advanced Therapies Rises | DelveInsight — Source | Via News | ViaNews EU